ArticleJournal of the American Academy of Dermatology2017
Serious infections among a large cohort of subjects with systemically treated psoriasis.
Article in Journal of the American Academy of Dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 40 citations in OpenAlex.
- COVID-19 susceptibility, severity, and vaccine effectiveness in patients with psoriasis: a nationwide cohort study in South Korea.Scientific reports · 2025Article
- Influence of psoriasis on infection risk and survival outcomes in patients with head and neck cancer: a retrospective cohort study.BMC cancer · 2025Article
- Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials.Therapeutic advances in chronic disease · 2023Article
- Management of Infections in Psoriatic Patients Treated with Systemic Therapies: A Lesson from the Immunopathogenesis of Psoriasis.Dermatology practical & conceptual · 2023Review
- Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use.Molecules (Basel, Switzerland) · 2022Article
- Incidence of COVID-19 in a cohort of dermatology patients receiving immunomodulating biologic medications.International journal of dermatology · 2021Article
- Review
- Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.Annals of the rheumatic diseases · 2020Article
- In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.Current rheumatology reports · 2019Review
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.American journal of clinical dermatology · 2019Article
- Reply to: Comment on "Serious infections among a large cohort of subjects with systemically treated psoriasis".Journal of the American Academy of Dermatology · 2018Article
- Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis.JAMA dermatology · 2018Article
- Infections in the era of immunobiologicals.Anais brasileiros de dermatologiaArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBiologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection.
objectiveTo estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting.
methodsWe identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up. Adjusted hazard ratios (aHRs) were calculated using Cox regression.
resultsAdjusting for age, sex, race or ethnicity, and comorbidities revealed a significantly increased risk for overall serious infection among patients treated with biologics as compared with those treated with nonbiologics (aHR, 1.31; 95% CI, 1.02-1.68). More specifically, there was a significantly elevated risk for skin and soft tissue infection (aHR, 1.75; 95% CI, 1.19-2.56) and meningitis (aHR, 9.22; 95% CI, 1.77-48.10) during periods of active biologic use. LIMITATIONS: Risk associated with individual drugs was not examined.
conclusionWe found an increased rate of skin and soft tissue infections among patients with psoriasis treated with biologic agents. There also was a signal suggesting increased risk for meningitis. Clinicians should be aware of these potential adverse events when prescribing biologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.